MÇMurat Çakır

Murat Çakır

*This is an algorithmically generated author record based on publicly available information.

Murat Çakır has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study

    by Ayşe Çolak, Zeynep Kumral, Önder Öztürk, Ayşegül Ülgen Kunak, Ali Nizami Elmas, Ömer Bedir, Medeni Karaduman, Naci Babat, Umut Uyan, Nurcemal Şentürk, et al.

    Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.


  • Kardiyak Aritmiler

    by Tayfun Gündüz, Murat Çakır, Halil İbrahim Tanrıseven, Eftal Murat Bakırcı, Muharrem Said Coşgun, Uğur Karabıyık, Cansu Coşgun

    Kardiyak aritmiler günlük hayatta sıkça karşılaşılan, hastanın yaşam kalitesinin bozulmasına ve hayatını kaybetmesine yol açan ciddi problemlerden biridir. Bu nedenle kardiyak aritmi konusunu güncel bilgiler kılavuzluğunda derleme ve kitap oluşturma ihtiyacı hissettik. Kardiyak aritmiler kitabı, taze yürekler olan asistanlarımızın da taze heyecanlarını paylaştıkları ilk kitap olması dolayısıyla ayrı bir önem taşımaktadır. Bu açıdan da asistanlarımıza ömür boyu mutluluklar ve başarılar diliyorum. Kardiyak Aritmiler kitabının mevcut haliyle öğrencilerimize, asistanlarımıza ve diğer tüm meslektaşlarımıza faydalı olacağı düşüncesindeyiz. Bu düşünceyle tüm insanlığa faydalı olmasını temenni ediyorum.